Osimertinib: Clinical Application and Market Overview of the Third Generation EGFR Targeting Drug

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) mainly used to treat non-small cell lung cancer (NSCLC), especially for patients with EGFR T790M mutations and first-line treatment-sensitive mutations. This article will start from its mechanism of action, clinical advantages, indications and market status, and introduce it systematically in five parts. The core content focuses on efficacy, safety and manufacturers, while the secondary content involves medication guidelines and patient management.

Mechanism of action and clinical advantages

Osimertinib inhibits tumor cell proliferation by irreversibly binding to EGFR mutant proteins (including T790M and exon 19 deletion, etc.). Compared with the first-generation EGFR-TKI (such as gefitinib), it has a stronger ability to penetrate the blood-brain barrier and has a significant effect on central nervous system metastasis. Clinical studies show that the median progression-free survival (PFS) of first-line treatment with osimertinib reaches 18.9 months, which is significantly better than traditional regimens (FLAURA trial, 2018). In addition, its incidence of adverse reactions (such as rash, diarrhea) is lower, and it is better tolerated by patients.

Indications and Medication Guide

Osimertinib is currently approved by the FDA and NMPA for: 1) second-line treatment of EGFR T790M mutation-positive NSCLC; 2) first-line treatment of EGFR-sensitive mutation (19del/L858R). Mutation status needs to be confirmed through tissue biopsy or liquid biopsy before use. The recommended dose is 80 mg orally daily, either on an empty stomach or after meals. If serious side effects such as interstitial pneumonia or QT interval prolongation occur, medication needs to be suspended and intervention required.

Market status and manufacturers

Osimertinib is developed by AstraZeneca under the trade nameTagrisso. As the world's first approved third-generation EGFR-TKI, its sales in 2022 will reach US$5.44 billion. In addition to original drugs, some domestic generic drugs have been approved, but original drugs still dominate. The following table lists major manufacturers and product information:

Summary and Outlook

Osimertinib has become the core treatment option for EGFR-mutated NSCLC due to its precise targeting and significant survival benefit. In the future, with the in-depth study of drug resistance mechanisms, its combined drug regimens (such as combination with anti-angiogenic drugs or chemotherapy) may further expand its indications. Patients need to use medications regularly under the guidance of doctors, and regularly monitor efficacy and safety.

Citing sources

1. Clinical trial data: FLAURA study (New England Journal of Medicine, 2018)
2. Drug instructions: Tagrisso (AstraZeneca China official website)
3. Production information: Announced by the National Medical Products Administration (NMPA)